Stock Events

Stock Events

Definium Therapeutics 

$45.05
955
-$1.13-2.45% 18:59 Today

Statistics

Day High
47.29
Day Low
44.59
52W High
49.7
52W Low
8.7
Volume
1,058,364
Avg. Volume
3,028,916
Mkt Cap
6.05B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-1.44
-1.12
-0.81
-0.49
Expected EPS
-0.558235
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-217.36MNet Income

Analyst Ratings

64.64Average Price Target
The highest estimate is 90.00.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DFTX. It's not an investment recommendation.
NVIDIA
32
NVDA
Amazon
22
AMZN
Apple
20
AAPL
Microsoft
20
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.86B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Mind Medicine's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap2.69B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor in the psychedelic medicine market.
GH Research
GHRS
Mkt Cap2.02B
GH Research is developing a novel therapeutic approach for mental health disorders using 5-MeO-DMT, competing in the same space as Mind Medicine's psychedelic-based treatments.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is involved in the development of psychedelic therapies, including psilocybin and MDMA, positioning it as a competitor in the psychedelic medicine industry.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, competing in the same therapeutic space as Mind Medicine.
TripAdvisor
TRIP
Mkt Cap1.26B
Red Light Holland is focused on the production, growth, and sale of a premium brand of magic truffles, entering the broader market of psychedelic substances that Mind Medicine is also targeting.
Noveris Health Sciences
MYCOF
Mkt Cap64.4M
Mydecine Innovations Group is a biotech company focusing on the development of psychedelic therapies, making it a competitor in the emerging field of psychedelic medicine.

About

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Show more...
CEO
Robert Barrow
Employees
106
Country
United States
ISIN
CA24477V1058
WKN
000A420P3

Listings

MU
DE
MMQ0.MU
STU
DE
MMQ0.STU
STU
DE
BGHM.STU
F
DE
MMQ0.F

0 Comments

Share your thoughts

FAQ

What is Definium Therapeutics stock price today?▼
The current price of DFTX is $45.05 USD — it has decreased by -2.45% in the past 24 hours. Watch Definium Therapeutics stock price performance more closely on the chart.
What is Definium Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Definium Therapeutics stocks are traded under the ticker DFTX.
What is Definium Therapeutics market cap?▼
Today Definium Therapeutics has the market capitalization of 6.05B
When is the next Definium Therapeutics earnings date?▼
Definium Therapeutics is going to release the next earnings report on November 05, 2026.
What were Definium Therapeutics earnings last quarter?▼
DFTX earnings for the last quarter are -1.44 USD per share, whereas the estimation was -0.54 USD resulting in a -166.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Definium Therapeutics revenue for the last year?▼
Definium Therapeutics revenue for the last year amounts to 0 USD.
What is Definium Therapeutics net income for the last year?▼
DFTX net income for the last year is -217.36M USD.
How many employees does Definium Therapeutics have?▼
As of August 19, 2026, the company has 106 employees.
In which sector is Definium Therapeutics located?▼
Definium Therapeutics operates in the Health & Wellness sector.
When did Definium Therapeutics complete a stock split?▼
Definium Therapeutics has not had any recent stock splits.
Where is Definium Therapeutics headquartered?▼
Definium Therapeutics is headquartered in NEW YORK, United States.